aTyr Pharma Inc.
3545 John Hopkins Road, Suite 250
San Diego
California
92121
United States
258 articles about aTyr Pharma Inc.
-
aTyr Pharma to Participate in April Investor Conferences
4/1/2024
aTyr Pharma, Inc. today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024.
-
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
3/14/2024
aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.
-
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
2/28/2024
aTyr Pharma, Inc. announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024.
-
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
2/21/2024
aTyr Pharma, Inc. today announced plans to initiate an Individual Patient Expanded Access Program (EAP) for its lead therapeutic candidate, efzofitimod, for patients with pulmonary sarcoidosis.
-
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
1/29/2024
aTyr Pharma, Inc. today announced that the company will present two posters at the Keystone Symposia on Myeloid Cell Diversity: From Fundamental Biology to Disease States, which is being held January 28 – 31, 2024, in Banff, Alberta, Canada.
-
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
1/18/2024
aTyr Pharma, Inc. announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company.
-
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
11/13/2023
aTyr Pharma, Inc. announced a poster presentation for its lead therapeutic candidate, efzofitimod, at the American College of Rheumatology Convergence 2023, which is being held November 10 – 15, 2023, in San Diego, CA.
-
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
11/9/2023
aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2023 results and provided a corporate update.
-
aTyr Pharma to Present at November 2023 Investor Conferences
11/1/2023
aTyr Pharma, Inc. announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at two upcoming investor conferences scheduled to take place in November 2023.
-
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILDMultiple centers in the U.S. are open for enrollment
10/31/2023
aTyr Pharma, Inc. today announced that it has dosed the first patient in its Phase 2 EFZO-CONNECT™ study.
-
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
9/11/2023
aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the results of a post-hoc analysis of data from its Phase 1b/2a study of efzofitimod in patients with pulmonary sarcoidosis.
-
aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
8/24/2023
aTyr Pharma, Inc. (Nasdaq: LIFE) today announced that Jill Broadfoot, Chief Financial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place September 11 – 13, 2023, in New York, NY.
-
aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update
8/9/2023
aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, announced second quarter 2023 results and provided a corporate update.
-
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic SclerosisPhase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to begin in the third quarter of 2023
6/22/2023
aTyr Pharma, Inc. announced that the European Commission granted orphan drug designation for the company’s lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis based on the opinion of the European Medicines Agency Committee for Orphan Medicinal Products.
-
aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference
6/20/2023
aTyr Pharma, Inc. announced that the company will present on its lead therapeutic candidate, efzofitimod, at the World Association for Sarcoidosis and Other Granulomatous Disorders Conference, which is scheduled to take place June 19 – 21, 2023, in Stockholm, Sweden.
-
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 09, 2023
6/9/2023
aTyr Pharma, Inc. announced that the Compensation Committee of aTyr’s Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 23,400 shares of its common stock, each with an exercise price of $2.26 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on June 8, 2023, the effective date of the grants.
-
aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)
6/6/2023
aTyr Pharma, Inc. today announced multiple presentations at the International Union of Biochemistry and Molecular Biology’s 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023), which is scheduled to take place June 4 – 9 in Ontario, Canada.
-
aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference
5/25/2023
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the 2023 Jefferies Healthcare Conference.
-
aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference
5/22/2023
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2023 International Conference.
-
aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference
5/11/2023
aTyr Pharma, Inc. announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 2023 RBC Capital Markets Global Healthcare Conference, which is scheduled to take place May 16 – 17, 2023, in New York, NY.